ClinicalTrials.gg
CompletedNCT06117514Updated Nov 7, 2023

Sudapyridine (WX-081) in Healthy Volunteers

A Phase 1 interventional study of Sudapyridine 30mg and Sudapyridine 100mg SAD in Healthy, sponsored by Shanghai Jiatan Pharmatech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Shanghai Jiatan Pharmatech Co., Ltd · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 8 months after the study started (first participant enrolled Feb 2019, registered Oct 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the safety, tolerability as well as pharmacokinetics of Sudapyridine (WX-081) in Chinese volunteers.

Read the detailed description

In this study, a single-center, randomized, double-blind, placebo-controlled, dose-ascending design was used to evaluate the safety, tolerability and pharmacokinetic characteristics of Sudapyridine (WX-081) tablets in healthy Chinese subjects using placebo as control.

This study was divided into two stages. The first stage evaluated the tolerance of single administration, pharmacokinetic characteristics, and the effect of food on PK. The second stage evaluated the tolerance of multiple administration and PK characteristics.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Shanghai Jiatan Pharmatech Co., Ltd is the lead sponsor of 11 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Weight: ≥50 kg; 19≤ (BMI) \< 26 kg/m2;
  • Considered healthy by the investigator based on a detailed history, thorough physical examination, clinical laboratory examination, 12-lead , and vital signs results;
  • No parenting plan and reliable during the trial period and within 3 months after the last dose.

Exclusion criteria

Exclusion Criteria:

  • Allergic to any drug of the same category or its ingredients;
  • A history of alcohol dependence or drug abuse;
  • Laboratory obvious abnormalities;
  • potent inducer or inhibitor had been taken within 30 days prior to enrollment;
  • Any serious cardiovascular, kidney, liver, blood, tumor, endocrine and metabolic, or rheumatic diseases.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (actual)

Study arms

  • Experimental
    Sudapyridine 30 mg single dose

    Participants received Sudapyridine 30 mg single dose orally.

    Drug: Sudapyridine 30mg

  • Experimental
    Sudapyridine 100 mg single dose

    Participants received Sudapyridine 100 mg single dose orally.

    Drug: Sudapyridine 100mg SAD

  • Experimental
    Sudapyridine 200 mg single dose

    Participants received Sudapyridine 200 mg single dose orally.

    Drug: Sudapyridine 200mg SAD

  • Experimental
    Sudapyridine 200 mg multiple doses

    Participants received Sudapyridine 200 mg orally for multiple doses.

    Drug: Sudapyridine 200mg MAD

  • Experimental
    Sudapyridine 300 mg multiple doses

    Participants received Sudapyridine 300 mg orally for multiple doses.

    Drug: Sudapyridine 300mg MAD

  • Placebo comparator
    Placebo 100 mg single dose

    Participants received Placebo 100 mg single dose orally.

    Other: Placebo tablet SAD

  • Placebo comparator
    Placebo 200 mg single dose

    Participants received Placebo 200 mg single dose orally.

    Other: Placebo 200mg SAD

  • Placebo comparator
    Placebo 200 mg multiple doses

    articipants received Placebo 200 mg orally for multiple doses.

    Other: Placebo tablet MAD

  • Placebo comparator
    Placebo 300mg multiple doses

    Participants received Placebo 300 mg orally for multiple doses.

    Other: Placebo tablet MAD

Interventions

  • Sudapyridine capsule 30mg, orally, single dose

    Also known as: Sudapyridine capsule 30mg SAD

  • Sudapyridine tablet, 100mg orally, single dose

    Also known as: Sudapyridine tablet 100mg SAD

  • Sudapyridine tablet, 200mg orally, single dose

    Also known as: Sudapyridine tablet 200mg SAD

  • Sudapyridine tablet, 200mg orally once a day for 14 days

    Also known as: Sudapyridine tablet 200mg MAD

  • Sudapyridine tablet, 300mg orally once a day for 14 days

    Also known as: Sudapyridine tablet 300mg MAD

  • OtherPlacebo tablet SAD

    Placebo tablet, 100mg orally, single dose

    Also known as: Placebo tablet 100mg

  • OtherPlacebo 200mg SAD

    Placebo tablet, 200mg orally, single dose

  • OtherPlacebo tablet MAD

    Placebo tablet, 200mg orally once a day for 14 days

    Also known as: Placebo tablet 200mg MAD

  • OtherPlacebo tablet MAD

    Placebo tablet, 300mg orally once a day for 14 days

    Also known as: Placebo tablet 300mg MAD

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration (Cmax) of Sudapyridine

    PK parameter

    Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose

  2. Time to reach plasma Cmax (Tmax) of Sudapyridine

    PK parameter

    Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose

  3. Area under the plasma concentration-time curve (AUC) of Sudapyridine

    PK parameter

    Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose

  4. Terminal elimination half-life (t½) of Sudapyridine

    PK parameter

    Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose

  5. Volume of distribution (Vd/F) of Sudapyridine

    PK parameter

    Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose

  6. Apparent clearance (CL/F) of Sudapyridine

    PK parameter

    Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose

  7. Elimination rate constant Ke of Sudapyridine

    PK parameter

    Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose

  8. Number of participants with adverse events (AEs) or Serious Adverse Events (SAEs)

    safety parameter

    Time frame: 0,1,2,3,4,6,8,12,24,48,72,96,120,144 hours post-dose

07

Study locations

1 site
  • Shanghai Xuhui District Central Hospital
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2019 to primary completion in Jul 2020, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2023
First posted
Nov 7, 2023
StartActual
Feb 13, 2019
Primary completionActual
Jul 2, 2020
CompletionActual
Jul 2, 2020
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06117514
Lead sponsor
Shanghai Jiatan Pharmatech Co., Ltd
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Feb 13, 2019
Primary completion
Jul 2, 2020
Completion
Jul 2, 2020
Last update
Nov 7, 2023

Study contacts

Yun Liu
principal investigator · Shanghai Xuhui District Central Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sudapyridine

Start the discussion